Modifying, deleting, or degrading protein ZFP574 reduces division of malignant B cells in lab

CHMP recommends approval of Calquence plus chemoimmunotherapy for first-line mantle cell lymphoma

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the EU for the treatment of adult patients with previously untreated mantle cell lymphoma who are not eligible for autologous hematopoietic stem cell transplantation.

April 04, 2025

Vol.51 No.13

Clinical Roundup

Investigational Orca-T treatment for hematologic malignancies meets primary endpoint in phase III trial

Orca Bio, a late-stage biotechnology company, on March 17 announced results from the pivotal phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with acute myeloid leukemia, acute lymphoblastic leukemia, high-risk myelodysplastic syndrome and mixed-phenotype acute leukemia. Orca-T is manufactured using highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from peripheral blood from either related or unrelated matched donors.

March 28, 2025

Vol.51 No.12

Drugs & Targets

EC expands approval for Breyanzi for r/r follicular lymphoma

The European Commission has granted approval to Breyanzi, a CD19-directed CAR T-cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

March 21, 2025

Vol.51 No.11

Accelerating translational research in leukemia: The City of Hope approach

As a physician-scientist, I navigate the intersection of laboratory research and clinical care every day. At City of Hope, our mission is to rapidly translate groundbreaking discoveries into effective treatments for patients with hematologic malignancies, particularly acute leukemias. This is possible due to a unique combination of infrastructure and culture combined with an unwavering sense of urgency.

Florida leukemia rates rising rapidly as population ages, study shows

Driven by a steady influx of retirees, Florida now has the highest leukemia rates of any U.S. state and the disease is the fastest-rising cancer type statewide, according to research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

March 14, 2025

Vol.51 No.10

Clinical Roundup

Combination therapy overcomes drug resistance in KRAS-G12C mutant cancers, study finds

Multidrug resistance in cancer can be overcome by combining a drug that blocks a key enzyme with another anticancer drug, according to a study in preclinical models led by researchers at UT Southwestern Medical Center.

February 28, 2025

Vol.51 No.08

Modifying, deleting, or degrading protein ZFP574 reduces division of malignant B cells in lab

YOU MAY BE INTERESTED IN

CHMP recommends approval of Calquence plus chemoimmunotherapy for first-line mantle cell lymphoma

Investigational Orca-T treatment for hematologic malignancies meets primary endpoint in phase III trial

EC expands approval for Breyanzi for r/r follicular lymphoma

Accelerating translational research in leukemia: The City of Hope approach

Florida leukemia rates rising rapidly as population ages, study shows

Combination therapy overcomes drug resistance in KRAS-G12C mutant cancers, study finds

Renew today!

Subscriber content